Major finding: TG4010 combined with first-line chemotherapy delays advanced NSCLC progression.

Approach: A randomized, controlled phase 2B study assessed the efficacy and safety of TG4010.

Future direction: Baseline immune status may predict clinical response to therapeutic vaccination.

This content is only available via PDF.
©2011 American Association for Cancer Research.
2011